Auxilium Pharma To Present Interim Data On XIAFLEX - Quick Facts

(RTTNews) - Auxilium Pharmaceuticals Inc. (AUXL), a specialty biopharmaceutical company, announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

The open-label Phase 4 study is evaluating 51 patients who had recurrence of a contracture in a joint that had been previously effectively treated with XIAFLEX. Patients were treated with up to three injections of XIAFLEX to the recurrent cord and were then evaluated for clinical outcome, changes in contracture and range of motion, physician assessment of improvement, patient satisfaction and safety. The interim analysis was conducted after all patients had completed their 30-day follow up assessments.

The company reported that: 87 percent of recurrent contractures of metacarpophalangeal joints were successfully retreated; 85 percent of recurrent contractures of proximal interphalangeal joints were successfully retreated; and retreatment with collagenase clostridium histolyticum was well tolerated.